Welcome to our dedicated page for Celanese Del SEC filings (Ticker: CE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Celanese Corporation (NYSE: CE) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Form 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. Celanese is a global specialty materials and chemical company in the basic organic chemical manufacturing industry, and its filings offer detailed insight into its financing activities, governance developments and operational decisions.
Recent Form 8-K filings describe a range of material events. Several filings outline registered offerings of senior notes by Celanese US Holdings LLC, a wholly owned subsidiary, including 7.000% Senior Notes due 2031 and 7.375% Senior Notes due 2034. These filings explain that net proceeds are used to repay borrowings under a five-year term loan credit agreement due 2027, fund cash tender offers for outstanding senior notes due 2027 and 2028, and support general corporate purposes, which may include repayment of other indebtedness.
Other 8-K reports cover cash tender offers for the company’s 6.665% Senior Notes due 2027 and 6.850% Senior Notes due 2028, including announcements of the commencement of tender offers, early results and increases in the maximum tender amount and series cap. Additional filings detail a revolving credit agreement providing a five-year unsecured revolving credit facility and an amendment to an existing term loan credit agreement, including new covenant terms.
Celanese filings also document operational and portfolio actions, such as the intended closure of an acetate tow production facility in Lanaken, Belgium, with associated expected non-cash accelerated depreciation and other shutdown costs, and the signing of a purchase and sale agreement to divest the Micromax® portfolio of products. Governance-related filings include the resignation of a Board member and the company’s explanation that the departure was not due to any disagreement on operations, policies or practices.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that help explain the key points of each document. Users can quickly understand the implications of Celanese’s 8-K disclosures, senior note offerings, credit agreements, tender offers and other reported events without reading every technical detail.
Celanese Corporation announced that its wholly owned subsidiary Celanese US Holdings LLC has launched cash tender offers to buy back up to an aggregate principal amount of $1,000,000,000 of its outstanding senior notes. The offers target its 6.665% Senior Notes due 2027 and 6.850% Senior Notes due 2028.
The 2028 notes are subject to a series cap, limiting purchases of that issue to a maximum aggregate principal amount of $100,000,000. The tender offers are being made on the terms and conditions described in an Offer to Purchase dated December 2, 2025, and represent a step in managing the company’s outstanding debt profile and interest-bearing obligations.
Celanese Corp (CE) reported an equity award to Chief Accounting Officer Aaron M. McGilvray. On 11/17/2025, he acquired 2,980 time-based restricted stock units (RSUs) of Celanese common stock at a price of $0 as a compensatory grant. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
The RSUs will vest, subject to continued employment, in two equal installments of 50% on November 17, 2026 and November 17, 2027. Following this grant, McGilvray beneficially owns 10,319.378 shares directly and 798.8018 shares indirectly through a 401(k) plan.
Celanese Corp (CE) reported an equity award to a senior executive. A Form 4 filing shows that an officer serving as SVP & General Counsel received 6,624 shares of Celanese common stock on 11/17/2025 in the form of time-based restricted stock units granted under the company’s Amended and Restated 2018 Global Incentive Plan. The award was recorded at a price of $0 per share, reflecting that it is a compensatory grant rather than an open-market purchase.
Each RSU represents the right to receive one share of common stock, with vesting subject to continued employment. The RSUs will vest 50% on November 17, 2026 and the remaining 50% on November 17, 2027. After this grant, the reporting person directly beneficially owned 20,459 shares, and an additional 624.623 shares were held indirectly through a 401(k) plan.
Celanese Corp (CE) director Kim K.W. Rucker filed a Form 4 reporting the acquisition of 7.29 shares of phantom stock on 11/12/2025, coded “A.” The filing lists a price of $39.12 for the derivative security.
Each phantom share represents the right to receive one share of common stock, with payment in stock under the company’s 2008 Deferred Compensation Plan after the director’s service ends. Following the transaction, 9,514.09 derivative securities were beneficially owned directly.
Celanese Corp (CE) director Deborah J. Kissire reported an acquisition of derivative securities on a Form 4. On 11/12/2025, she acquired 4.54 units of phantom stock (Transaction Code A) at a price of $39.12 per the derivative security entry.
Each phantom stock unit represents the right to receive one share of Common Stock. Following the transaction, she beneficially owned 5,921.288 derivative securities directly. The phantom stock relates to dividend equivalents under the company’s 2008 Deferred Compensation Plan and becomes payable in shares after her service as a director ends.
Celanese (CE) director Jay V. Ihlenfeld filed a Form 4 reporting an acquisition of 7.84 shares of phantom stock on 11/12/2025 (Code A). Following this transaction, he beneficially owns 10,235.059 derivative securities, held directly.
Each phantom share represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan and becomes payable in common shares after the director’s service ends, as provided in the plan.
Celanese Corp (CE) reported a Form 4 for director Kathryn Hill. On 11/12/2025, she acquired 2.26 units of phantom stock (transaction code A) at a derivative price of $39.12. After this transaction, she beneficially owned 2,948.87 derivative securities directly.
Each phantom stock unit represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the company’s 2008 Deferred Compensation Plan and becomes payable in shares of common stock following the end of her service as a director.
Celanese Corporation (CE) director Timothy Go reported an acquisition of 0.86 phantom stock units on 11/12/2025 (Transaction Code: A). Each phantom stock unit represents the right to receive one share of common stock.
The units reflect dividend equivalents credited under the company’s 2008 Deferred Compensation Plan and become payable in common stock following the end of his service as a director. After this transaction, his directly held derivative securities balance is 1,115.57 units.
Celanese (CE) director Edward G. Galante reported an acquisition of 5.21 phantom stock units on 11/12/2025 under a Form 4 filing. Following this transaction, he beneficially owns 6,802.765 derivative securities.
The transaction was coded A (acquired). Each phantom stock unit represents the right to receive one share of common stock. The reported phantom stock reflects dividend equivalents on compensation deferred under the Company’s 2008 Deferred Compensation Plan and becomes payable in shares of common stock after his service as a director ends. The filing lists a Price of Derivative Security of $39.12.
Celanese Corporation (CE) reported a large GAAP loss driven by non‑cash impairments. For Q3 2025, net sales were $2,419 million and net loss was $1,353 million as Other (charges) gains, net totaled $1,491 million. Operating loss was $1,275 million. Year‑to‑date, net sales were $7,340 million with a net loss of $1,173 million.
The quarter included a goodwill impairment of about $1.0 billion in Engineered Materials, an additional $98 million linked to the Micromax® held‑for‑sale classification, and a $346 million impairment of certain trade names. Cash from operations rose to $894 million for the nine months, lifting cash to $1,440 million and shareholders’ equity to $3,954 million. The company signed an agreement on October 28, 2025 to divest its Micromax® portfolio to Element Solutions for approximately $500 million in cash, subject to adjustments and approvals. Celanese also announced plans to close its Lanaken, Belgium facility, expecting $70–$90 million of exit and shutdown costs during 2026–2028.
Debt stood at $11,655 million long‑term (net), with March 2025 note issuances of $700 million (2030, 6.500%), €750 million (2031, 5.000%) and $1,100 million (2033, 6.750%), alongside tender offers for €552 million (2026) and $500 million (2027) notes.